AZD6088 Single Ascending Dose Study

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 After Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers

The aims of the study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD6088 following single ascending dose administration in healthy male and non-fertile females.

Inclusion Criteria:

• Caucasian male and non-fertile female healthy volunteers aged ≥18 to ≤55 years with suitable veins for cannulation or repeated venipuncture.
• Clinically normal physical findings including supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by the investigator.
• Normal and suitable EEG, as judged by a neurologist

Exclusion Criteria:

• History of any clinically significant disease or disorder which for instance includes CNS disorder or CV disorder.
• Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator.
• Any clinically important abnormalities in the ECG.